Vor Biopharma Inc.

Equities

VOR

US9290331084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 15/07/2024 BST			5-day change	1st Jan Change
0.9707 ^USD	+2.18%		+7.13%	-56.86%

07-01	Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 3000E Value Index	CI
07-01	Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 2000 Value Index	CI

Vor Bio to Present at B. Riley Securities' 3rd Annual Oncology Conference

January 13, 2023 at 03:07 pm

Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities' 3rd Annual Oncology Conference.

B. Riley Securities' 3rd Annual Oncology Conference - Fireside Chat

Date:	Wednesday, January 18, 2023

Time: 12:00 PM ET

A live webcast of the presentation will be available via the Investors section of the Company's website at www.vorbio.com. An archived replay of the webcast will also be available following the conference.

About Vor Bio

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant.

Contact:

Sarah Spencer

Tel: +1 857-242-6076

Email: sspencer@vorbio.com

Latest news about Vor Biopharma Inc.

Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 3000E Value Index	06-30	CI
Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 2000 Value Index	06-30	CI
Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 2500 Index	06-30	CI
Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 3000 Index	06-30	CI
Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 2000 Index	06-30	CI
Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 3000 Value Index	06-30	CI
Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 2500 Value Index	06-30	CI
Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 2000 Dynamic Index	06-30	CI
Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell Small Cap Comp Value Index	06-30	CI
Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell Small Cap Completeness Index	06-30	CI
Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 3000E Index	06-30	CI
Voyager Therapeutics Names Nathan Jorgensen as Finance Chief	06-13	MT
Vor Biopharma Inc. Announces Management Appointments, Effective June 21, 2024	06-10	CI
Nathan Jorgensen Resigns as Chief Financial Officer of Vor Biopharma Inc., Effective June 21, 2024	06-10	CI
Oppenheimer Adjusts Vor Biopharma Price Target to $10 From $15, Maintains Outperform Rating	05-13	MT
Vor Biopharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Vor Biopharma Inc. Appoints Fouad Namouni as Class II Director	05-02	CI
Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating	03-21	MT
Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating	03-21	MT
Vor Biopharma Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-20	CI
Vor Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Vor Biopharma Doses First Blood Cancer Patient With Leukemia Treatment, Provides Cash Runway Guidance	01-17	MT
Vor Bio Doses First AML Patient with VCAR33	01-17	CI
Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference	11-09	CI
Vor Biopharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI

Chart Vor Biopharma Inc.

Duration

Period

More charts

Company Profile

Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Companyâs lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9707 USD

Average target price

14.06 USD

Spread / Average Target

+1,348.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VOR BIOPHARMA INC.	-56.86%	66.26M
MODERNA, INC.	+22.15%	46.56B
LONZA GROUP AG	+45.94%	41.67B
IQVIA HOLDINGS INC.	-2.37%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	32.4B
CELLTRION, INC.	-6.35%	28.1B
ICON PUBLIC LIMITED COMPANY	+20.42%	28.18B
UNITED THERAPEUTICS CORPORATION	+48.83%	14.52B
MEDPACE HOLDINGS, INC.	+45.00%	13.74B
BIO-TECHNE CORPORATION	+0.06%	12.17B

Other Biotechnology & Medical Research